[1] Ming-Chao T, Chen CH, Po-Lin T, et al. Does nucleos(t)ide analogues treatment affect renal function in chronic hepatitis B patients who have already decreased eGFR? A longitudinal study:. Plos One, 2016, 11:e0149761-e0149763.
[2] 中华医学会肝病学分会. 慢性乙型肝炎防治指南2010年更新版. 中华实验和临床感染病杂志(电子版), 2011, 05:50-60.
[3] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2010年版). 中国实用乡村医生杂志, 2012,20:54-109.
[4] Lian JS, Zeng LY, Chen JY, et al. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol, 2013, 19:6278-6283.
[5] Hong P, Liu J, Min YM, et al. Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis. J Clin Pharmacol, 2014, 54:189-200.
[6] 刘亚允, 梁雪松. 慢性乙型肝炎病人长期小剂量服用阿德福韦酯抗病毒治疗相关肾损伤. 药学服务与研究, 2017,29:445-448.
[7] Wang CC, Tseng KC, Hsieh TY, et al. Assessing the durability of entecavir-treated hepatitis B using quantitative HBsAg. Am J Gastroenterol, 2016, 111:1286-1294. |
